S-Nitrosocaptopril

Drug Profile

S-Nitrosocaptopril

Alternative Names: SnoCap

Latest Information Update: 27 Feb 2008

Price : $50

At a glance

  • Originator Shiga University of Medical Science
  • Developer GlaxoSmithKline; Shiga University of Medical Science
  • Class Vasodilators
  • Mechanism of Action ACE inhibitors; Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Angina pectoris; Heart failure; Hypertension; Ischaemic heart disorders

Most Recent Events

  • 14 Jun 2001 No-Development-Reported for Hypertension in USA (IV)
  • 23 Jan 2001 Glaxo Wellcome has merged with SmithKline Beecham to form GlaxoSmithKline
  • 08 Sep 1998 Preclinical development for Hypertension in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top